Biotech M&A in 2012: The Good, Bad, and Ugly

Biotech M&A in 2012: The Good, Bad, and Ugly

Embedded Link

Biotech M&A in 2012: The Good, Bad, and Ugly – Forbes
The numbers are in on the 2012 Pharma/Biotech M&A performance, at least according to our friends at HBM Partners. They’ve released another well-annotated deal report and database. The quick summa…

Google+: View post on Google+

Published by

Cliff

Walking Enthusiast, Technology Transfer Advisor @ Concordia University, Intellectual Property Valuation Expert @ Kalotem & Amateur Photographer.